atai Life Sciences — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
Cambrian Bio is a clinical-stage drug development company creating precision therapeutics that target metabolic pathways which decline with age, such as AMPK and mTOR.
BiotechHealthtechLongevityNew York, US
James G. Peyer(Executive Officer, Director)inJames Peyer(CEO, Founder, Board Director)inJames Peyer, PhD(Founder)inMark Nuttall(Chief Business Officer)inRuth Thieroff-Ekerdt(Chief Medical Officer)inWilliam DeVaul(Executive Officer)in
Board seatChristian Angermayer· per SEC Form D · $37.6M raise · filed Jan 2025
Co-investorsCatalio Capital Management, LPFuture VenturesKhosla VenturesKorify CapitalSprint VcStrawberry Creek Ventures+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.